Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Tong Ren Tang Technologies Co. Ltd.
北京同仁堂科技發展股份有限公司

(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1666)

ANNOUNCEMENT ON RESULTS OF SUBSIDIARY

Reference is made to the announcement (the "**Announcement**") dated 20 March 2026 published by Beijing Tong Ren Tang Chinese Medicine Company Limited ("**Tong Ren Tang Chinese Medicine**", and its subsidiaries, collectively referred to as the "**Tong Ren Tang Chinese Medicine Group**"), a subsidiary of Tong Ren Tang Technologies Co. Ltd. (the "**Company**"), whose shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 3613), in relation to the annual results of Tong Ren Tang Chinese Medicine Group for the year ended 31 December 2025.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following audited consolidated financial information of Tong Ren Tang Chinese Medicine Group for the year ended 31 December 2025 together with the comparative figures for the previous year as set out in the Announcement.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Year ended 31 December	
	2025	2024
	HK$'000	HK$'000
Revenue	**1,513,357**	1,611,644
Cost of sales	**(587,781)**	(546,315)
Gross profit	**925,576**	1,065,329
Distribution and selling expenses	**(207,131)**	(300,205)
General and administrative expenses	**(183,280)**	(191,791)
Net impairment losses on financial assets	**(61,586)**	(1,949)
Other gains, net	**(1,340)**	5,540
Operating profit	**472,239**	576,924
Finance income	**46,835**	57,274
Finance costs	**(5,660)**	(6,481)
Finance income, net	**41,175**	50,793
Share of profits/(losses) of investments accounted for using the equity method	**(8,725)**	2,056
Profit before income tax	**504,689**	629,773
Income tax expense	**(87,830)**	(100,606)
Profit for the year	**416,859**	529,167
Profit attributable to:		
Owners of the Company	**397,216**	500,278
Non-controlling interests	**19,643**	28,889
	416,859	529,167
Earnings per share attributable to owners of the Company for the year (expressed in HK$ per share)		
Basic and diluted earnings per share	**0.47**	0.60

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Year ended 31 December	
	2025	2024
	HK$'000	HK$'000
Profit for the year	**416,859**	529,167
Other comprehensive income:		
Item that may be reclassified to profit or loss		
Currency translation differences attributable to owners of the Company	**7,452**	(15,520)
Share of other comprehensive income of joint ventures	**718**	110
Share of other comprehensive income/(loss) of associates	**693**	(588)
Reclassification adjustment for a foreign operation disposed of during the year attributable to owners	**25**	-
Item that will not be reclassified to profit or loss		
Change in fair value of financial asset at fair value through other comprehensive income/(loss)	**(1,830)**	810
Currency translation differences attributable to non-controlling interest, net	**2,124**	(3,382)
Reclassification adjustment for a foreign operation disposed of during the year attributable to non-controlling interest, net	**(958)**	-
Other comprehensive income/(losses) for the year	**8,224**	(18,570)
Total comprehensive income for the year	**425,083**	510,597
Attributable to:		
Owners of the Company	**404,274**	485,090
Non-controlling interests	**20,809**	25,507
Total comprehensive income for the year	**425,083**	510,597

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	As at 31 December	
	2025	2024
	HK$'000	HK$'000
Assets		
Non-current assets		
Property, plant and equipment	**225,460**	211,111
Right-of-use assets	**200,008**	201,234
Intangible assets	**64,494**	67,313
Investments accounted for using equity method	**42,585**	53,546
Financial asset at fair value through other comprehensive income	**6,813**	8,643
Prepayments and deposits	**24,361**	16,445
Deferred income tax assets, net	**32,261**	35,486
	595,982	593,778
Current assets		
Inventories	**1,341,633**	1,589,016
Trade receivables and other current assets	**443,899**	556,978
Short-term bank deposits with original maturities exceeding three months	**51,377**	46,679
Cash and cash equivalents	**2,227,847**	1,773,074
	4,064,756	3,965,747
Total assets	**4,660,738**	4,559,525
Equity and liabilities		
Equity attributable to owners of the Company		
Share capital	**938,789**	938,789
Reserves		
- Other reserves	**(50,078)**	(58,377)
- Retained earnings	**3,299,179**	3,194,948
	4,187,890	4,075,360
Non-controlling interests	**180,971**	171,074
Total equity	**4,368,861**	4,246,434

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)

	As at 31 December	
	2025	2024
	HK$'000	HK$'000
Liabilities		
Non-current liabilities		
Borrowings	**71**	142
Lease liabilities	**74,171**	65,799
Deferred income tax liabilities, net	**7,185**	8,708
Retirement benefit obligations	**3,602**	3,088
	85,029	77,737
Current liabilities		
Borrowings	**71**	71
Trade and other payables	**125,611**	157,308
Lease liabilities	**52,227**	57,408
Current income tax liabilities	**28,939**	20,567
	206,848	235,354
Total liabilities	**291,877**	313,091
Total equity and liabilities	**4,660,738**	4,559,525

By order of the Board

Tong Ren Tang Technologies Co. Ltd.

Zhang Yi

Chairman of the Board

Beijing, the PRC

20 March 2026

As at the date of this announcement, the Board comprises Mr. Zhang Yi, Mr. Zhang Chun You, and Ms. Wen Kai Ting as executive Directors, Ms. Du Xin and Ms. Feng Li as non-executive Directors, Ms. Chan Ching Har, Eliza, Mr. Zhan Yuan Jing and Mr. Siu, Paul Yu Hay as independent non-executive Directors, and Mr. Zhu Dong Sheng as employee Director.